Primary Brachial Plexus Tumors: Clinical Experiences of 143 Cases

Jia, Xiaotian; Yang, Jianyun; Lin, Chen; Yu, Cong; Kondo, Tadashi

doi:10.1016/j.clineuro.2016.07.009

Cited by 35 publications

(56 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We obtained similar clinical characteristics of brachial plexus schwannoma as those reported in literature [3,4,[6][7][8][9][10]. Brachial plexus schwannoma could be a painless or painful mass.…”

Section: Discussionsupporting

confidence: 69%

“…Jia et al published a large case series of 143 patients with primary brachial plexus tumors in 2016. In his series, there are 119 schwannoma and 12 neurofibromas [3]. Schwannomas are most frequently found in the head and neck region, which comprises 25% of all Schwannomas.…”

Section: Introductionmentioning

confidence: 99%

“…It comprises of only 5% of all tumours of upper limb [1]. The two most common brachial plexus region tumors are schwannomas and neurofibromas [2][3][4]. Both are benign and arise from the nerve sheath.…”

Section: Introductionmentioning

confidence: 99%

“…[3,4,6]. Brachial plexus schwannoma can present as neck mass, axillary mass, supraclavicular mass or apical lung mass [7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Brachial Plexus Schwannoma: Report of 4 cases with Intralesional Enucleation

Chan¹,

Ip²

2017

J Clin Case Rep

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 69%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…[3,4,6]. Brachial plexus schwannoma can present as neck mass, axillary mass, supraclavicular mass or apical lung mass [7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Brachial Plexus Schwannoma: Report of 4 cases with Intralesional Enucleation

Chan¹,

Ip²

2017

J Clin Case Rep

View full text Add to dashboard Cite

“…Among these, three genes have been previously reported to be associated with TKI resistance: the receptor tyrosine kinase-like orphan receptor 1 (ROR1), Sal-like protein 4 (SALL4), and signal transducer CD24. ROR1 was previously reported to sustain signaling for multiple receptor tyrosine kinases and overcome TKI resistance in non-small cell lung cancers 43) . Hupfeld et al reported that TK inhibition facilitates cooperation of transcription factor SALL4 and ATP-binding cassette transporters A3 in eliciting drug resistance in intrinsic chronic myelogenous leukemia cells 44) .…”

Section: Discussionmentioning

confidence: 99%

Secretomics identifies follistatin as a predictive biomarker for response to treatment with tyrosine kinase inhibitors in synovial sarcoma

Qiao

Kito²,

Takai³

et al. 2017

J. Electrophor

Self Cite

View full text Add to dashboard Cite

SUMMARYSarcoma is a rare malignancy with an aggressive clinical course. Tyrosine kinase inhibitors (TKIs) have emerged as effective drugs in targeted therapy for malignancies; in particular, pazopanib was recently approved for the treatment of sarcoma. However, as only a limited proportion of patients exhibit favorable response to treatment with TKIs, predictive biomarkers of response to these drugs are urgently needed. In this study, we attempted to identify predictive biomarkers for response to TKIs in synovial sarcoma. We performed a magnetic bead-based assay (Bio-Plex) using synovial sarcoma cell culture supernatant and validated the results by ELISA and western blotting. Cellular protein and mRNA expression levels of candidate biomarkers were evaluated by western blotting and RT-PCR. Gene expression profiling of candidate biomarkers was conducted by meta-analysis of publicly available gene expression data from 149 patients with synovial sarcoma. We found that follistatin (FST) was significantly highly expressed in TKI-resistant cells. Moreover, cell proliferation was decreased following gene silencing of FST. Meta-analysis revealed that the mRNA expression of FST varied among the 149 patients with synovial sarcoma, and that 23 genes were co-expressed with FST; these included genes encoding receptor tyrosine kinase-like orphan receptor 1, Sal-like protein 4, and signal transducer CD24. This study suggested that FST represents a candidate predictive biomarker for response to treatment with TKIs in synovial sarcoma. Secretomics is a promising approach for predictive biomarker exploration. The utility of FST as a predictive biomarker for response to treatment with TKIs in synovial sarcoma should be further validated using clinical samples.

show abstract